Скачать или смотреть Durvalumab + FLOT: New Standard of Care for Gastric/GEJ Adenocarcinoma? | MATTERHORN Trial Results

Exciting news from the 2025 ESMO Congress! The phase 3 MATTERHORN trial shows that adding durvalumab (Imfinzi) to FLOT chemotherapy significantly improves overall survival in patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma. This video breaks down the key findings, including:
Statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo + FLOT.
Consistent OS benefit across most patient subgroups, regardless of PD-L1 status.
Improved event-free survival (EFS) as the primary endpoint.
Potential for a new global standard of care for this patient population.
We'll discuss the study design, patient characteristics, and previous trial data that led to this groundbreaking result. Stay informed about the latest advancements in gastric cancer treatment!